EOLS
Evolus, Inc.
$9.30
+0.25
(+2.76%)
Mkt Cap
612.45M
Volume
684,831
52W Range
3.86-9.31
Sector
Healthcare
Beta
1.36
EPS (TTM)
-0.52 USD
P/E Ratio
-8.31
Revenue (TTM)
316.49M USD
Rev Growth (5Y)
+39.4%
EPS Growth (5Y)
N/A
Company Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.18M | 266.27M | 202.09M | 148.62M | 99.67M | 56.54M | 34.92M | 0 | 0 | 0 | 0 |
| Net Income | (51.64M) | (50.42M) | (61.69M) | (74.41M) | (46.81M) | (163.01M) | (90.03M) | (46.87M) | (4.48M) | (20.07M) | (31.11M) |
| EPS | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Free Cash Flow | (50.72M) | (19.47M) | (35.63M) | (87.85M) | (34.36M) | (61.01M) | (97.95M) | (25.68M) | (13.04M) | (13.27M) | (36.38M) |
| FCF / Share | -0.79 | -0.31 | -0.63 | -1.57 | -0.69 | -1.81 | -3.47 | -1.05 | -0.55 | -0.71 | -1.96 |
| Operating CF | (42.27M) | (18.00M) | (34.01M) | (84.91M) | (33.39M) | (57.87M) | (93.38M) | (25.67M) | (13.04M) | (13.27M) | (36.38M) |
| Total Assets | 225.87M | 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | 240.44M | 171.84M | 152.23M | 77.50M | 81.30M |
| Total Debt | 155.00M | 129.98M | 126.55M | 74.42M | 74.74M | 138.32M | 96.55M | 16.90M | 211.33M | 59.76M | 46.17M |
| Cash & Equiv | 53.83M | 86.95M | 62.84M | 53.92M | 146.26M | 102.56M | 109.89M | 93.16M | 0 | 0 | 4.00M |
| Book Value | (23.11M) | 5.52M | (20.69M) | 18.50M | 81.88M | (72.96M) | 79.46M | (123.03M) | (75.54M) | (7.11M) | 12.00M |
| Return on Equity | N/A | -9.13 | N/A | -4.02 | -0.57 | N/A | -1.13 | N/A | N/A | N/A | -2.59 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.08M | 73.14M | 90.30M | 68.97M | 69.39M | 68.52M | 78.95M | 61.09M | 66.91M | 59.33M | 61.00M | 50.02M |
| Net Income | (8.05M) | (10.67M) | 130,000 | (15.74M) | (17.14M) | (18.89M) | (6.79M) | (19.17M) | (11.35M) | (13.11M) | (11.83M) | (16.92M) |
| EPS | -0.12 | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 | -0.11 | -0.30 | -0.18 | -0.22 | -0.21 | -0.30 |
| Free Cash Flow | (2.36M) | (11.64M) | 10.66M | (16.83M) | (27.06M) | (17.49M) | 3.45M | (7.13M) | (7.72M) | (11.41M) | 452,000 | (1.46M) |
| FCF / Share | -0.04 | -0.18 | 0.17 | -0.26 | -0.42 | -0.27 | 0.06 | -0.11 | -0.12 | -0.19 | 0.01 | -0.03 |
| Operating CF | (3.59M) | (9.95M) | 12.83M | (14.67M) | (24.79M) | (15.63M) | 4.81M | (5.72M) | (6.47M) | (10.62M) | 813,000 | (924,000) |
| Total Assets | 248.02M | 220.65M | 225.87M | 219.00M | 228.80M | 213.36M | 232.57M | 229.61M | 233.77M | 226.18M | 189.00M | 167.97M |
| Total Debt | 164.80M | 164.90M | 155.00M | 154.89M | 154.91M | 130.20M | 129.98M | 129.88M | 126.75M | 126.65M | 126.55M | 101.44M |
| Cash & Equiv | 45.17M | 49.79M | 53.83M | 43.52M | 61.74M | 67.89M | 86.95M | 85.03M | 93.67M | 96.96M | 62.84M | 38.69M |
| Book Value | (30.90M) | (28.78M) | (23.11M) | (28.76M) | (18.65M) | (6.60M) | 5.52M | 5.89M | 19.31M | 18.44M | (20.69M) | (19.37M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -1.23 | -3.25 | -0.59 | -0.71 | N/A | N/A |
EOLS News
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
Evolus (NASDAQ:EOLS) Reaches New 52-Week High – Time to Buy?
Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
Evolus: The Injectable Platform Is Becoming The Real Moat
Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus Q2 Earnings Call Highlights